M. Shapiro

发表

Long‐term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors

T. Brümmendorf, H. Kantarjian, J. Cortes, 2015, American journal of hematology.

Response to Miller et al: resistant mutations in CML and Ph(+) ALL – role of ponatinib

G. Devgan, M. Woloj, E. Matczak, 2015, Biologics : targets & therapy.

Acute myeloid leukemia: a retrospective claims analysis of resource utilization and expenditures for newly diagnosed patients from first-line induction to remission and relapse

W. Irish, C. Gunnarsson, L. Gache, 2017, Current medical research and opinion.

Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study

T. Brümmendorf, H. Kantarjian, J. Cortes, 2018, Haematologica.

Long‐term patient‐reported outcomes from an open‐label safety and efficacy study of bosutinib in Philadelphia chromosome–positive chronic myeloid leukemia patients resistant or intolerant to prior therapy

T. Brümmendorf, H. Kantarjian, J. Cortes, 2017, Cancer.

Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure

D. Cella, A. Reisman, J. Whiteley, 2016, Current medical research and opinion.

Long‐term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome‐positive leukemias treated with bosutinib

T. Brümmendorf, H. Kantarjian, J. Cortes, 2016, American journal of hematology.

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.

E. Giné, M. Czuczman, J. Winter, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, controlled trial of recombinant human interleukin‐11 in patients with active Crohn's disease

B. Sands, M. Safdi, B. Salzberg, 2002, Alimentary pharmacology & therapeutics.

Randomized, Double Blind Controlled Trial of Subcutaneous Recombinant Human Interleukin-11 Versus Prednisolone in Active Crohn's Disease

J. Schulzke, B. Bokemeyer, E. Stange, 2006, The American Journal of Gastroenterology.

Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States.

H. Henk, J. Whiteley, M. Woloj, 2015, Clinical therapeutics.

Assessment of Early Molecular Response As a Predictor of Long-Term Clinical Outcomes in the Phase 3 BELA Study

T. Brümmendorf, H. Kantarjian, J. Cortes, 2012 .

Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors

G. Demetri, P. Richardson, A. Elias, 1998, Cancer.

Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease.

A. Buchman, S. Hanauer, B. Sands, 1999, Gastroenterology.

Safety and Clinical Activity of the Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) in Combination with Rituximab in Follicular Lymphoma or Diffuse Large B-Cell Lymphoma: Preliminary Report of a Phase 1/2 Study

E. Giné, M. Czuczman, B. Coiffier, 2008 .

Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors

A. Zhu, L. Appleman, A. Lockhart, 2007, Cancer Chemotherapy and Pharmacology.

Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus.

J. Maroto, C. White, A. Berkenblit, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial

R. F. Johnston, Robert W. Taylor, Steven C. Johnson, 1994 .

Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.

S. Opal, R. Greenman, C. Fisher, 1994, JAMA.

Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma

T. Stuhlmiller, A. Blackham, Suresh Nair, 2022, Melanoma research.

Up-Front Tandem High-Dose Chemotherapy Compared With Standard Chemotherapy With Doxorubicin and Paclitaxel in Metastatic Breast Cancer: Results of a Randomized Trial

L. Goldstein, M. Shapiro, 2006 .

Clinical Activity of the Immunoconjugate CMC-544 in B-Cell Malignancies: Preliminary Report of the Expanded Maximum Tolerated Dose (MTD) Cohort of a Phase 1 Study.

E. Giné, M. Czuczman, A. Rohatiner, 2006 .

Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib

T. Brümmendorf, H. Kantarjian, J. Cortes, 2015, British journal of haematology.

Intralymphatic immunotherapy for mountain cedar pollinosis: A randomized, double-blind, placebo-controlled trial.

S. Silvers, M. Shapiro, C. Thompson, 2020, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Long-term bosutinib (BOS) in patients (pt) with chronic phase (CP) chronic myeloid leukemia (CML) after prior imatinib (IM) failure.

T. Brümmendorf, H. Kantarjian, J. Cortes, 2015 .

Acute myeloid leukemia: a retrospective claims analysis of resource utilization and expenditures for newly diagnosed patients from first-line induction to remission and relapse

W. Irish, C. Gunnarsson, L. Gache, 2017, Current medical research and opinion.

Long-term evaluation of vascular toxicity in patients with Ph+ leukemias treated with bosutinib.

T. Brümmendorf, H. Kantarjian, J. Cortes, 2014 .

Is Cancer Solvable? Towards Efficient and Ethical Biomedical Science

Jeff Shrager, Mark Shapiro, William Hoos, 2019, Journal of Law, Medicine & Ethics.

Safety of Neratinib (HKI-272) in Combination with Capecitabine in Patients with Solid Tumors: A Phase 1/2 Study.

Miguel Martín, J. Cortés, C. Saura, 2009 .